What is HC Wainwright’s Estimate for MIRM FY2027 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at HC Wainwright decreased their FY2027 EPS estimates for Mirum Pharmaceuticals in a report issued on Monday, January 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.04 per share for the year, down from their previous forecast of $0.86. HC Wainwright has a “Buy” rating and a $130.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ FY2028 earnings at $1.29 EPS and FY2029 earnings at $3.57 EPS.

Several other analysts have also recently weighed in on the company. Evercore ISI reaffirmed an “outperform” rating and set a $101.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Stifel Nicolaus raised their target price on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Finally, Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.92.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $100.85 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $101.50. The company’s 50-day moving average is $78.97 and its 200 day moving average is $71.75. The stock has a market capitalization of $5.18 billion, a P/E ratio of -117.27 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) EPS.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, insider Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the transaction, the insider owned 11,305 shares of the company’s stock, valued at $1,020,502.35. The trade was a 37.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Peter Radovich sold 3,143 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $302,325.17. Following the sale, the chief operating officer directly owned 23,286 shares in the company, valued at $2,239,880.34. This trade represents a 11.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 32,429 shares of company stock valued at $3,039,396 in the last ninety days. Corporate insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. MCF Advisors LLC lifted its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares in the last quarter. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000. Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. Quarry LP purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $41,000. Finally, CWM LLC boosted its stake in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the last quarter.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long‑term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52‑Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer‑range estimates — mixed guidance that tempers but does not negate the bullish long‑term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ≈$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near‑term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.